Cancerous disease modifying antibodies
AssigneeArius Research, Inc.
InventorsDavid Young, Susan Hahn, Helen Findlay
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
Claims20
A monoclonal antibody or cellular cytotoxicity inducing ligand characterized by an ability to competitively inhibit binding of the isolated monoclonal antibody encoded by the clone deposited with the ATCC as PTA-4890 to its target antigen.
A monoclonal antibody or cellular cytotoxicity inducing ligand characterized by an ability to competitively inhibit binding of the isolated monoclonal antibody encoded by the clone deposited with the ATCC as PTA-4889 to its target antigen.
Dependencies are inferred from the claim text.